Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PCSK9-IN-29
Cat. No.:
OB0425LY-215
Appearance:
Solid
Purity:
99.44%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
PCSK9-IN-29 is a selective PCSK9 inhibitor involved in the regulation of cholesterol metabolism.
Synonyms:
1233353-86-0; 2,3,10-Trimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-9-yl 3-fluorobenzenesulfonate
CAS No.:
1233353-86-0
Compound CID:
50898972
Formula:
C26H26FNO6S
Formula Weight:
499.55
Specification
Target:
LDLR; PCSK9
Pathway:
Metabolic enzyme/Protease
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
PCSK9-IN-29 can be used in studies of non-alcoholic fatty liver disease and obesity.
